Mar 13 |
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
|
Mar 13 |
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
|
Feb 21 |
Guggenheim starts Spruce Biosciences at buy, cites near-term catalysts
|
Jan 30 |
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
Jan 22 |
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
|
Jan 5 |
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
|
Jan 4 |
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
|
Nov 13 |
Spruce Biosciences GAAP EPS of -$0.30 beats by $0.05
|
Nov 13 |
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
|